Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
14.07
-0.13 (-0.92%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.

It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.

In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo.

The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.

The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals logo
Country United States
Founded 1996
IPO Date Nov 29, 2000
Industry Biotechnology
Sector Healthcare
Employees 147
CEO Raul Rodriguez

Contact Details

Address:
611 Gateway Blvd, Suite 900
South San Francisco, California 94080
United States
Phone 650 624 1100
Website rigel.com

Stock Details

Ticker Symbol RIGL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001034842
CUSIP Number 766559603
ISIN Number US7665596034
Employer ID 94-3248524
SIC Code 2834

Key Executives

Name Position
Raul R. Rodriguez President, Chief Executive Officer and Director
Dean L. Schorno CPA Executive Vice President and Chief Financial Officer
Raymond J. Furey J.D. Executive Vice President, General Counsel and Corporate Secretary
David A. Santos Executive Vice President and Chief Commercial Officer
Julie Patel Senior Vice President of Human Resources
Dr. Esteban S. Masuda Executive Vice President of Research
Joseph Lasaga Executive Vice President and Chief Business Officer
Dr. Lisa Rojkjaer M.D. Executive Vice President and Chief Medical Officer
Tarek Sallam Vice President of Marketing

Latest SEC Filings

Date Type Title
Sep 19, 2024 8-K Current Report
Sep 3, 2024 8-K Current Report
Aug 9, 2024 EFFECT Notice of Effectiveness
Aug 7, 2024 UPLOAD Filing
Aug 6, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 6, 2024 8-K Current Report
Aug 6, 2024 10-Q Quarterly Report
Aug 2, 2024 S-3 Registration statement under Securities Act of 1933
Jun 27, 2024 8-K Current Report
Jun 25, 2024 8-K Current Report